HTGC stock news · Hercules Capital, Inc.
Get alerts for HTGC
Follow Hercules Capital, Inc. (HTGC) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for HTGCSeveral Wall Street analysts changed their ratings and price targets for Hercules Capital, showing a mostly positive view.
Good for HTGCHercules Capital received 3 bullish analyst ratings, including an upgrade and a raised target, against 1 neutral rating. The balance leans positive, but ratings are not company results.
Hercules Capital shares its financial results for the third quarter of 2026.
Good for HTGCHTGC reported rising investment income, a higher value per share, and coverage for its base dividend. The results point to a stronger outlook despite fewer early loan repayments.
Hercules Capital shared details from its earnings call for the third quarter of 2026.
Good for HTGCHercules Capital reported record lending activity and income through Q3, with income covering its base payout. Expected Q4 loan repayments temper, but do not erase, the positive read.
Hercules Capital, Inc. has signed a big deal for a $400 million public offering.
NeutralHercules Capital issued $400 million in notes and may use the cash to repay debt or make investments. The new interest payments are a concern, but the filing does not show a clear change in its outlook.
Top Wall Street analysts share their thoughts on 3 financial stocks that pay over 10% in dividends.
NeutralHercules Capital’s analysts kept favorable ratings but cut their price targets, and the company sold notes that must be repaid with interest. The report gives no clear sign of a change in its business outlook.
Rocket Pharmaceuticals, Inc. has signed a big loan deal for up to $150 million.
NeutralHercules Capital is named as agent for the lenders in Rocket's loan, but the filing gives no amount attributable to Hercules. It does not show a clear change to Hercules Capital's outlook.